Dendreon Defends Provenge’s Stake Against Arrival Of Abiraterone
Executive Summary
Dendreon Corp. is defending Provenge's position as the “foundation of care” for castration-resistant prostate cancer, following the recent approval of Johnson & Johnson’s Zytiga, and looking ahead to other novel drugs coming down the pike.
You may also be interested in...
Data At ASCO From J&J Zytiga Trial’s Early End = Intel For Medivation’s MDV3100 Program
Details from the COU-302 trial of Johnson & Johnson’s Zytiga, stopped early for efficacy in March, were released at the American Society of Clinical Oncology meeting, revealing to Medivation/Astellas insights on how to tweak their ongoing registrational trial for enzalutamide (MDV3100) in the pre-chemo prostate cancer space.
Zytiga Study Supports Expansion To Early Patient Population
J&J halts Phase III trial of its prostate cancer drug six months early based on the recommendation of the trial’s independent data monitoring committee.
Dendreon Says Provenge On Track For Steady Growth, Downplays Rising Competition
In an earnings call Nov. 2, Dendreon reported Q3 growth in sales and uptake of its prostate cancer active immunotherapy Provenge despite near term pressures.